Receiving a liver transplant is a life-changing event, but the years that follow bring their own challenges. Many recipients gain significant weight and develop metabolic problems, including elevated blood sugar, unfavorable cholesterol profiles, and rising cardiovascular risk. Over time, those changes can stress the transplanted organ itself, contributing to a condition called allograft steatosis, where fat accumulates in the new liver. Researchers have been searching for safe ways to address this pattern.
Glucagon-like peptide-1 receptor agonists, commonly called GLP-1 RAs, are a class of peptides that mimic a gut hormone involved in insulin secretion, appetite signaling, and blood sugar regulation. They have been studied extensively in people with obesity and type 2 diabetes, but their use in liver transplant recipients raises distinct questions. Could the peptide interfere with immunosuppressant drugs? Could it stress the grafted organ? A multicenter observational study published in a peer-reviewed transplant journal set out to answer exactly those questions.
Study design and participants
The research team conducted a retrospective cohort study spanning four international transplant centers, pulling data from January 2010 through June 2025. They identified 104 adult liver transplant recipients who had used GLP-1 RA therapy regularly. Most, about 68 percent, had started the peptide specifically to manage post-transplant diabetes. The most frequently used agent was a subcutaneous form of semaglutide, a GLP-1 receptor agonist peptide, at a median weekly dose of roughly 0.82 milligrams.
To create a fair comparison, the researchers matched GLP-1 RA users with non-users on several variables: age, sex, obesity status, diabetes status, the year of transplant, and the center where care was received. The final matched analysis included 80 GLP-1 RA users compared with 116 non-users. Statistical modeling used linear mixed models with multiple imputation to account for missing data across the follow-up period.
Weight and metabolic outcomes
Over the one-year observation period, liver transplant recipients using GLP-1 RA peptides lost an average of 3.8 kilograms, a 3.9 percent reduction in body weight that reached statistical significance (p less than 0.001). Body mass index fell by an average of 1.6 units, representing about a 5 percent drop. Glycated hemoglobin, a marker of long-term blood sugar control, improved by 0.48 percentage points on average.
In the matched comparison, the GLP-1 RA group lost approximately 3.4 kilograms more than the non-user group over the same period, a difference the statistical analysis flagged as significant (p equals 0.009). The hemoglobin A1c gap between groups was 0.43 percentage points in favor of GLP-1 RA users (p equals 0.042). The researchers also noted modest improvement in lipid profiles among users, though the lipid findings were described as less pronounced than the weight and glycemic effects.
Allograft and immunosuppression safety
One of the central concerns in this population is whether any new therapy might disturb the delicate balance of immunosuppression that keeps the transplanted liver safe. The study tracked liver function tests and immunosuppressant trough levels throughout the observation period. Both remained stable across the GLP-1 RA group, with no statistically meaningful shifts detected.
Researchers also looked specifically for T-cell-mediated rejection, a serious complication in which the immune system attacks the donor organ. No increased rate of this event appeared in the GLP-1 RA group compared with matched controls. Allograft dysfunction, defined through a combination of clinical and laboratory criteria, was likewise not elevated among peptide users.
Cardiovascular events and tolerability
The study tracked major adverse cardiovascular events, a composite endpoint that typically includes heart attack, stroke, and cardiovascular death. No increase in these events was observed in the GLP-1 RA group relative to matched non-users over the one-year window. The authors note this is a meaningful finding given that cardiovascular disease is a leading cause of long-term mortality after liver transplantation.
On the tolerability front, the abstract reports that no treatment-limiting adverse events occurred in the 104 GLP-1 RA users followed. This does not mean the peptide was without any side effects, but none rose to the level of requiring patients to stop therapy. The researchers flag that dosing in this cohort was relatively low compared with trials in the general population, which they suggest may have contributed to both the moderate weight loss and the favorable safety picture.
Limitations and what comes next
The authors are candid about the study's boundaries. As an observational, retrospective design, it cannot prove causation the way a randomized controlled trial can. Patients who received GLP-1 RA therapy were not randomly assigned, so unmeasured differences between users and non-users could still influence the results, even after matching. The relatively low peptide doses used across the cohort also mean the findings may not generalize to higher-dose regimens now common in non-transplant populations.
The study covered a broad fifteen-year window, during which transplant care practices and available GLP-1 RA formulations evolved considerably. Pooling data across four centers and multiple years introduces heterogeneity that the statistical models can only partially address. The one-year follow-up window, while useful for a safety signal, does not tell researchers what happens to allograft health or metabolic parameters over five or ten years of continued peptide use.
The research team concludes by calling for prospective, randomized trials in liver transplant recipients. The observational data are encouraging enough to support moving to that next level of evidence, and the authors argue that the absence of major safety signals removes one barrier that might have made trial sponsors hesitant.
Context within GLP-1 peptide research
GLP-1 receptor agonist peptides work by binding to receptors found in the pancreas, brain, gut, and other tissues. In the pancreas, activation of these receptors increases insulin release in a glucose-dependent way, meaning the effect is stronger when blood sugar is high and diminishes as levels normalize. In the brain, the peptides appear to reduce appetite signaling. In the gut, they slow stomach emptying, which contributes to feelings of fullness after smaller meals.
Prior research in non-transplant populations has shown meaningful reductions in body weight and blood sugar with GLP-1 RA peptides, along with signals of cardiovascular benefit in people with established heart disease. The transplant population introduces unique biology because immunosuppressant drugs like calcineurin inhibitors can themselves promote diabetes and metabolic dysfunction. Whether GLP-1 peptides interact with those drugs has been a research gap, and this multicenter study provides some early reassurance, though the authors are careful not to overstate conclusions from a retrospective design.
For researchers and clinicians following the field, this study adds to a small but growing body of literature suggesting that GLP-1 RA peptides warrant serious investigation in specialty populations where metabolic complications are common but evidence has historically been thin.
